Health insurer Elevance raises annual profit forecast
Reuters
Published Jul 20, 2022 06:19AM ET
Updated Jul 20, 2022 06:40AM ET
(Reuters) -Elevance Health Inc lifted its annual earnings forecast on Wednesday after strength in the unit that houses its pharmacy benefits management business, IngenioRx, helped the company sail past market estimates for quarterly profit.
Larger rival UnitedHealth Group Inc (NYSE:UNH) had also raised its full-year profit outlook last week as a slow recovery in non-urgent medical procedures and lower COVID-care costs help it rein in medical expenses.
Net profit for Elevance, which was previously known as Anthem, fell to $1.65 billion, or $6.79 per share, in the three months ended June 30, from $1.79 billion, or $7.25 per share, a year earlier.
Excluding items, the company reported earnings of $8.04 per share, above analysts' estimates of $7.74, according to IBES estimates from Refinitiv.
It now expects adjusted earnings to be greater than $28.70 per share for the year, up from its prior forecast of more than $28.40 per share.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.